Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the diagnostic part of the study:
- People who are suspected of having muscle-invasive bladder cancer (a type of bladder cancer that has grown into the muscle wall of the bladder)
- People who have completed all three required scans: FAPI PET/MRI, FDG PET/MRI, and a standard MRI
- People who have complete medical records, lab results, and tissue sample (biopsy) results available
For the treatment response part of the study:
- People who have been diagnosed with muscle-invasive bladder cancer
- People who have completed all three required scans before starting neoadjuvant therapy (treatment given before surgery to shrink the cancer)
- People who have complete medical records, lab results, and tissue sample results available
Who may not be able to join:
For the diagnostic part of the study:
- People who also have another type of cancer
- People who are not having surgery as part of their treatment
- People who received neoadjuvant therapy (pre-surgery treatment) before having surgery
- People who have had an allergic reaction to contrast dye or similar substances used in scans
- People with serious problems affecting the heart, lungs, liver, or kidneys
- People whose medical records or test results are incomplete
For the treatment response part of the study:
- People who also have another type of cancer
- People who did not complete all three required scans after finishing neoadjuvant therapy
- People who have had an allergic reaction to contrast dye or similar substances used in scans
- People with serious problems affecting the heart, lungs, liver, or kidneys
- People whose medical records or test results are incomplete
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xue-Yi Xue, Master, First Affiliated Hospital of Fujian Medical University
Phone: 13235907575
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Diagnostic Sensitivity; Diagnostic Specificity; Positive Expected Value (PPV); Negative Expected Value (NPV); Positive Likelihood Ratio (PLR); Negative Likelihood Ratio (NLR); Youden Index; Standardized uptake values peak, maximum, and mean (SUVpeak , SUVmax, SUVmean); Tumor-to-Background Ratio (TBR); Complete Remission (CR); Partial Remission (PR); Stable Disease (SD); Progressive Disease (PR); Complete Metabolic Response (CMR); Partial Metabolic Response (PMR); Stable Metabolic Disease (SMD); Progressive Metabolic Disease (PMD); Pathologic Response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.